Introduction {#sec0005}
============

Coronaviruses (CoVs) are single-stranded RNA viruses that belong to the *Coronaviridae* family. They spread among a wide range of hosts, presenting clinically with an array of symptoms, ranging from common cold-like to severe, sometimes lethal, respiratory infection. The new virus, responsible for the pandemic, was initially termed as "2019-nCoV", but it has since been renamed "SARS-CoV-2" by the Coronavirus Study Group (CSG), a body that belongs to the International Committee on Taxonomy of Viruses (ICTV), as it is believed to be familiar with the SARS-CoV, a pathogen that causes severe acute respiratory syndrome (SARS). The recent SARS-CoV-2 is closely associated with SARS-CoV, sharing 80 % identity in RNA sequence ([@bib0260]; [@bib0115]). With first cases in humans being recorded in December 2019, SARS-CoV-2 is responsible for an outbreak of respiratory disease called COVID-19 (Coronavirus Disease 2019). The full spectrum of COVID-19 ranges from benign, self-resolving respiratory distress to severe progressive pneumonia, multiple organ failure, and death ([@bib0300]). The city of Wuhan, in the province of Hubei in central China has been declared as the epicenter of the pandemic, with Huanan seafood market being one of the first locations where SARS-CoV-2 potentially crossed the species barrier at the animal-human interface. Pioneering research undertaken in Shenzhen, near Hong Kong, by a group of clinicians and scientists from the University of Hong Kong, provided the first piece of evidence, that SARS-CoV-2 can been transmitted from human-to-human ([@bib0115]). The new threat quickly spread from China and is currently classified as a pandemic by the World Health Organization (WHO). Many countries are implementing extraordinary measures in order to provide their societies with adequate strategies of disease prevention and monitoring ([@bib0115]; [@bib0700]).

For the time being, there is neither a vaccination or a specific SARS-CoV-2 targeted antiviral treatment available. Multiple countries have attempted varying pharmacologic strategies to combat the disease, involving currently established antivirals, different modes of oxygen therapy or mechanical ventilation. COVID-19 pandemic requires rapid development of efficacious therapeutic strategies, in the pursuit of which three concepts are being applied: (*i*) The first approach relies on testing currently known antiviral agents and verifying their clinical usefulness ([@bib0335]; [@bib0415]). (*ii*) Another modality is based on molecular libraries and databases, allowing for high computing power and simultaneous verification of millions of potential agents ([@bib0415]; [@bib0120]). (*iii*) Lastly, the third strategy involves targeted therapy, intended to disrupt the genome and functioning of the virus. Precisely designed particles would disrupt the crucial steps of viral infection, such as cell surface binding and internalization. Unfortunately, *in vitro* activity does not necessarily translate into efficacy in the *in vivo* setting, due to differing pharmacodynamic and pharmacokinetic properties ([@bib0415]; [@bib0710]). The main groups of therapeutic agents that can be useful in COVID-19 treatment involve antiviral drugs, selected antibiotics, antimalarials, and immunotherapeutic drugs. In the present paper, we aim to summarize current progress and insights that have emerged from the use of pharmaceuticals in COVID-19.

Hydroxychloroquine and other antimalarials {#sec0010}
==========================================

In one of the newest dissertations published by a French team of doctors, a positive influence of hydroxychloroquine (HCQ) in patients infected by SARS-CoV-2 was observed ([@bib0245]). Furthermore, another *in vitro* trial showed that both chloroquine (CQ) and its hydroxylated derivative, HCQ, possess beneficial properties. HCQ, an agent with universally established antimalarial, anti-inflammatory, and analgesic properties, is widely used in the treatment of malaria. The US Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) are currently working on establishing randomized clinical trials that aim to confirm the usefulness of CQ and its derivatives in combating CoV-2 virus infection ([@bib0030], [@bib0035]). In the beginning of February 2020, China included CQ with its derivatives as one of the therapeutic options in SARS-CoV-2 treatment, with South Korea soon following this path ([@bib0240]; [@bib0540]). The mechanism of action of antimalarial agents has not been well elucidated -- it is believed to be pleiotropic, affecting T-cells, cytokine production, and others. Graphical representation of HCQ action can be seen in [Fig. 1](#fig0005){ref-type="fig"} . Additional anti-inflammatory effect can be attributed to the inhibition of extracellular matrix metalloproteinases ([@bib0455]; [@bib0370]; [@bib0620]). In this case, the potential mechanism of action of CQ and its hydroxylated derivative is attributed to the blockade of viral infection via an alkalization of endosomal (and lysosomal) pH; it should be emphasized that the above acidic pH is required for virus-host cell fusion ([@bib0005]; [@bib0690], [@bib0685]). Furthermore, the agents are believed to disrupt SARS-CoV cell receptor glycosylation ([@bib0575]).Fig. 1Graphical representation of HCQ action.It is believed that most important pathways involve lysosomal enzyme stabilization, antigen presentation suppression, T-cell stimulation inhibition, or cytokine cascade blockade. HCQ inhibits the proliferation of T-cells and monocytes, and decreases the production of pro-inflammatory cytokines (Il-6, Il-17, IFN-α, IFN-λ, TNF-α). Additionally, it inhibits antibody and prostaglandin (PG) production. It decreases thrombocyte aggregation, lipid levels, insulin secretion, as well as oxidative stress ([@bib0455]). Another mechanism that contributes to its antimalarial properties involves the inhibition of toll-like-receptors, namely TLR-3, TLR-7, and TLR-9, in response to microbial antigens that under normal conditions induce inflammatory response. Furthermore, antimalarial drugs inhibit PG production and lipid peroxidation. Decreasing PG production involves the inhibition of phospholipase A2 activity.Fig. 1

It has been shown that HCQ presents *in vitro* antiviral properties against SARS-CoV ([@bib0075]). Its clinical safety profile is superior to that of CQ (in a long-term setting), which allows for higher daily dose, and results in fewer drug-drug interactions ([@bib0650]; [@bib0430]). A clinical trial aiming to assess the influence of HCQ on the outcome of patients infected with SARS-CoV-2 by Gautret et al., compared patients receiving HCQ and controls, concentrating on viral load reduction ([@bib0245]) (all clinical trials are summarized in [Table 1](#tbl0005){ref-type="table"} and [Fig. 2](#fig0010){ref-type="fig"} ). The study enrolled hospitalized patients with confirmed COVID-19. Patients were stratified into three categories: asymptomatic (16.7 %); upper respiratory tract infection (URTI; 61.1 %), presenting as rhinitis, pharyngitis, or isolated fever and muscle pain; lower respiratory tract infections (LRTI; 22.2 %), who suffered from symptoms of pneumonia or bronchitis. Twenty patients were administered HCQ sulfate orally, and 16 served as the control group. Among patients treated with HCQ, 6 were also treated with azithromycin, in order to prevent superimposed bacterial infection. The percentage of patients with absence of viral loads on nasopharyngeal swab sample RT-PCR was significantly higher in the treatment group than in controls, on days 3, 4, 5 and 6 of follow-up. On day 6, which was considered the endpoint, in 70 % of patients treated with HCQ viral load disappearance was observed, in comparison with 12.5 % in the control group (p = 0.001) ([@bib0245]).Table 1Summary of the clinical trials on COVID-19 treatment to date (16th of April 2020).Table 1Therapeutic agentsClinical Trial IDNumber of participantsCommentsAdalimumabChiCTR20000 3008960compared to standard treatmentAdamumab + TozumabChiCTR20000 3058060compared to standard treatmentAnakinraNCT04341584240-AnakinraNCT0433971220compared to tocilizumabAnakinraNCT0432402154compared to emapalumab and standard treatmentAngiotensin 1-7NCT0433266660-ASC09NCT0426127060compared to ritonavir; combined with oseltamivirASC09NCT04261907160compared to lopinavir/ritonavir; combined with ritonavirAtovaquoneNCT0433942625combined with azithromycinAzithromycinNCT04341727500compared to chloroquine and hydroxychloroquineAzithromycinNCT043244631500compared to chloroquineAzithromycinNCT04339816240combined with hydroxychloroquineAzithromycinNCT04336332160compared to hydroxychloroquine; combined with hydroxychloroquineAzithromycinNCT043321072271-Azithromycin + HydroxychloroquineNCT04322123630compared to hydroxychloroquineAzithromycin + HydroxychloroquineNCT04321278440compared to hydroxychloroquineAzvudineChiCTR20000 2985320compared to standard treatmentAzvudineChiCTR20000 3004140-AzvudineChiCTR20000 3042430-AzvudineChiCTR20000 3048710-Baloxavir marboxilChiCTR20000 2954430compared to favipiravir and standard treatmentBaloxavir marboxilChiCTR20000 2954830compared to favipiravir and lopinavir/ritonavirBaricitinibNCT0432027760-BaricitinibNCT0434023280-BaricitinibNCT043219931000compared to hydroxychloroquine, lopinavir/ritonavir and sarilumabBLD-2660NCT04334460120-Camostat MesylateNCT04321096180-CD24FcNCT04317040230-CD24FcNCT04317040230-ChloroquineChiCTR20000 2954220compared to standard treatmentChloroquineChiCTR20000 29609200compared to lopinavir/ritonavirChloroquineChiCTR20000 29741112compared to lopinavir/ritonavirChloroquineChiCTR20000 2982645-ChloroquineChiCTR20000 29837120-ChloroquineChiCTR20000 29935100-ChloroquineChiCTR20000 29939100compared to standard treatmentChloroquineChiCTR20000 2997510-ChloroquineChiCTR20000 2998880compared to standard treatmentChloroquineChiCTR20000 29992100compared to standard treatment; combined with hydroxychloroquineChloroquineChiCTR20000 30031120-ChloroquineChiCTR20000 3041730-ChloroquineChiCTR20000 3071880compared to standard treatmentChloroquineChiCTR20000 29898100compared to hydroxychloroquineChloroquineChiCTR20000 29899100compared to hydroxychloroquineChloroquineNCT04341727500compared to azithromycin and hydroxychlorquineChloroquineNCT043244631500compared to azithromycinChloroquineNCT04323527440-ChloroquineNCT04333628210compared to standard treatmentChloroquineNCT04331600400-ChloroquineNCT04328493250compared to standard treatmentCiclesonideNCT04330586141compared to standard treatment; combined with hydroxychloroquineColchicineNCT043284802500-ColchicineNCT043226826000-ColchicineNCT04322565100-CSA0001ChiCTR20000 3093910-Danoprevir/RitonavirChiCTR20000 3000050compared to IFN-α, peginterferon α-2a and standard treatmentDanoprevir/RitonavirChiCTR20000 3025960compared to standard treatmentDanoprevir/RitonavirChiCTR20000 3047220compared to standard treatmentDarunavir/CobicistatNCT0425227430compared to standard treatmentDarunavir/CobicistatNCT043040533040-Darunavir/RitonavirNCT0429172950compared to IFN-α, lopinavir/ritonavir and peginterferon α-2a; combined with IFN-αDAS181NCT043244894-DeferoxamineNCT0433355050compared to standard treatmentDefibrotideNCT0433520150-Dexamethasone2020-001113-21 (EU-CTR)2000compared to IFN β-1a and lopinavir/ritonavirDexamethasoneNCT04327401290-Dihydroartemisinin/PiperaquineChiCTR20000 3008240compared to IFN-α + umifenovir; combined with antiviral treatmentEbastineChiCTR20000 30535100combined with IFN-α and lopinavirEmapalumabNCT0432402154compared to anakinra and standard treatmentEmtricitabine/Tenofovir + Lopinavir/RitonavirChiCTR20000 29468120-FavipiravirChiCTR20000 2954430compared to baloxavir marboxil and standard treatmentFavipiravirChiCTR20000 2954830compared to baloxavir marboxil and lopinavir/ritonavirFavipiravirChiCTR20000 2960090compared to lopinavir/ritonavir; combined with IFN-αFavipiravirChiCTR20000 2999660-FavipiravirChiCTR20000 3011320compared to ritonavirFavipiravirChiCTR20000 30254240compared to umifenovirFavipiravirChiCTR20000 30987150combined with chloroquineFavipiravirJPRN jRCTs04119012086-FavipiravirNCT0427376360combined with bromohexine, IFN α-2b and umifenovirFavipiravirNCT04310228150compared to tocilizumab; combined with tocilizumabFavipiravirNCT04336904100-FingolimodNCT0428058830compared to standard treatmentFluvoxamineNCT04342663152-GD31ChiCTR20000 29895160-Hydroxychloroquine2020-000890-25 (EU-CTR)25-HydroxychloroquineChiCTR20000 29559300-HydroxychloroquineChiCTR20000 2974078compared to standard treatmentHydroxychloroquineChiCTR20000 29868200compared to standard treatmentHydroxychloroquineChiCTR20000 29898100compared to chloroquineHydroxychloroquineChiCTR20000 29899100compared to chloroquineHydroxychloroquineChiCTR20000 30054100compared to standard treatmentHydroxychloroquineNCT0426151730compared to standard treatmentHydroxychloroquineNCT04315896500-HydroxychloroquineNCT043159483100compared to IFNβ-1a, lopinavir/ritonavir and remdesivirHydroxychloroquineNCT04316377202compared to standard treatmentHydroxychloroquineNCT04342221220-HydroxychloroquineNCT043405442700-HydroxychloroquineNCT04338698500compared to azithromycin and oseltamivirHydroxychloroquineNCT04335552500compared with azithromycin, hydroxychloroquine and standard treatment; combined with azithromycinHydroxychloroquineNCT04334512600combined with azithromycinHydroxychloroquineNCT043343821550combined with azithromycinHydroxychloroquineNCT04329832300combined with azithromycinHydroxychloroquineNCT04329572400combined with azithromycinHydroxychloroquineNCT0432827275combined with azithromycinHydroxychloroquineNCT043236311116compared to standard treatmentHydroxychloroquineNCT043219931000compared to baricitinib, lopinavir/ritonavir and sarilumabHydroxychloroquineNCT04342169400-HydroxychloroquineNCT04341727500compared to azithromycin and chloroquineHydroxychloroquineNCT0434149386compared to nitazoxanideHydroxychloroquineNCT043349671250compared to standard treatmentHydroxychloroquineNCT04333654210compared to standard treatmentHydroxychloroquineNCT04332991510-HydroxychloroquineNCT04321616700compared to remdesivir and standard treatmentHydroxychloroquine + IFN β-1b + Lopinavir/RitonavirIRCT20100228 003449N2730-Hydroxychloroquine + IFN β-1b + Lopinavir/RitonavirIRCT20100228 003449N2830-Hydroxychloroquine + Lopinavir/RitonavirJPRN jRCTs03119022750-Hydroxychloroquine + Lopinavir/Ritonavir + Sofosbuvir/LedipasvirIRCT20100228 003449N2950-Hydroxychlorquine + Camostat MesylateNCT04338906334-IFN α-1bChiCTR20000 29989300-IFN α-1bNCT04293887328compared to standard treatmentIFN α-1b + Lopinavir/Ritonavir + RibavirinChiCTR20000 29387108-IFN α-2bNCT0427376360combined with bromohexine, favipiravir and umifenovirIFN α-2b + Lopinavir/RitonavirChiCTR20000 3016620-IFN β-1a2020-001023-14 (EU-CTR)400-IFN β-1a2020-000936-23 (EU-CTR)3000compared to lopinavir/ritonavir and remdesivirIFN β-1a2020-001113-21 (EU-CTR)2000compared to dexamethasone and lopinavir/ritonavirIFN β-1aNCT0434376860compared to hydroxychloroquine + lopinavir / ritonavir and IFN β-1b; combined with hydroxychloroquine + lopinavir / ritonavirIFN β-1bNCT0434376860compared to hydroxychloroquine + lopinavir / ritonavir and IFN β-1a; combined with hydroxychloroquine + lopinavir / ritonavirIFN β-1b + RibavirinNCT0427668870combined with lopinavir/ritonavirIFN-αChiCTR20000 2949690compared to lopinavir/ritonavir; combined with lopinavir/ritonavirIFN-αChiCTR20000 2960090compared to lopinavir/ritonavir and favipiravirIFN-αChiCTR20000 29638100compared to rSIFN-coIFN-αChiCTR20000 3000050compared to danoprevir/ritonavir, peginterferon α-2a and standard treatmentIFN-αNCT0429172911compared to darunavir/ritonavir, lopinavir/ritonavir and peginterferon α-2aIFN-α and Lopinavir/RitonavirNCT04251871150-IFN-α and Lopinavir/RitonavirNCT04275388348-IFX-1NCT04333420130compared to standard treatmentInterleukin-2ChiCTR20000 3016780compared to standard treatmentIvermectineNCT0434309250combined with Hydroxychloroquine; compared to placeboIxekizumabChiCTR20000 3070340compared to antiviral therapy; combined with antiviral therapyLeflunomideChiCTR20000 30058200compared to standard treatmentLeronlimabNCT0434365170-LevamisoleNCT0433147030compared to standard treatment; combined with budesonide, formeterol and hydoxychloroquine + lopinavir/ritonavirLopinavir/Ritonavir2020-000936-23 (EU-CTR)3000compared to IFN β-1a and remdesivirLopinavir/Ritonavir2020-001113-21 (EU-CTR)2000compared to dexamethasone and IFN β-1aLopinavir/RitonavirChiCTR20000 29308160compared to standard treatmentLopinavir/RitonavirChiCTR20000 2940060-Lopinavir/RitonavirChiCTR20000 2949690compared to IFN-α; combined with IFN-αLopinavir/RitonavirChiCTR20000 29539328compared to standard treatmentLopinavir/RitonavirChiCTR20000 2954830compared to baloxavir marboxil and favipiravirLopinavir/RitonavirChiCTR20000 29573480combined with IFN-α and umifenovirLopinavir/RitonavirChiCTR20000 2960090compared to favipiravir; combined with IFN-αLopinavir/RitonavirChiCTR20000 29609200compared to chloroquineLopinavir/RitonavirChiCTR20000 3018760compared to standard treatmentLopinavir/RitonavirChiCTR20000 3021880-Lopinavir/RitonavirNCT04252885125compared to standard treatment and umifenovirLopinavir/RitonavirNCT04255017400compared to oseltamivir and umifenovirLopinavir/RitonavirNCT04261907160compared to ASC09Lopinavir/RitonavirNCT0429172911compared to darunavir/ritonavir, IFN-α and peginterferon α-2aLopinavir/RitonavirNCT043159483100compared to hydroxychloroquine and remdesivir; combined with IFN β-1aLopinavir/RitonavirNCT04330690440compared to standard careLopinavir/RitonavirNCT043219931000compared to baricitinib, hydroxychloroquine and sarilumabLosartanNCT04340557200-LY3127804NCT04342897200-MeplazumabNCT0427524528-MethylprednisoloneNCT04263402100-MethylprednisoloneChiCTR20000 2938648compared to standard treatmentMethylprednisoloneChiCTR20000 29656100compared to standard treatmentMethylprednisoloneNCT0424459180compared to standard treatmentMethylprednisoloneNCT04273321400compared to standard treatmentMethylprednisoloneNCT04323592104compared to standard treatmentNaproxenNCT04325633584compared to standard treatmentNitazoxanideNCT0434149386compared to hydroxychloroquineNivolumabNCT0434314492compared to standard treatmentOseltamivirNCT04255017400compared to lopinavir/ritonavir and umifenovirOseltamivirNCT0426127060compared to ASC09 and ritonavirOseltamivirNCT0430329980compared to favipiravir, lopinavir/ritonavir and standard treatment; combined with chloroquine, darunavir/ritonavir and lopinavir/ritonavirPD-1 monoclonal antibodyChiCTR20000 3002840compared to standard treatmentPD-1 monoclonal antibodyNCT04268537120compared to standard treatment and thymosinPeginterferon Lambda-1aNCT04331899120-Peginterferon α-2aChiCTR20000 3000050compared to danoprevir/ritonavir, IFN-α and standard treatmentPeginterferon α-2aNCT0429172911compared to darunavir/ritonavir, IFN-α and lopinavir/ritonavirPiclidenosonNCT0433347240compared to standard treatmentPolyinosinic polycytidylic acidChiCTR20000 2977640compared to standard treatmentPUL-042NCT04312997100-Remdesivir2020-000841-15 (EU-CTR)400compared to standard treatmentRemdesivir2020-000842-32 (EU-CTR)600compared to standard treatmentRemdesivir2020-000936-23 (EU-CTR)3000compared to IFN β-1a and lopinavir/ritonavirRemdesivirNCT04252664308-RemdesivirNCT04257656453-RemdesivirNCT04280705394-RemdesivirNCT04292730600compared to standard treatmentRemdesivirNCT04292899400compared to standard treatmentRemdesivirNCT043159483100compared to hydroxychloroquine, IFN β-1a and lopinavir/ritonavirRemdesivirNCT04321616700compared to hydroxychloroquine and standard treatmentRhACE2 APN01NCT04335136200-rhG-CSFChiCTR20000 30007200compared to standard treatmentRibavirinChiCTR20000 3092230combined with IFN α-2a and umifenovirRitonavirChiCTR20000 3011320compared to favipiravirrSIFN-coChiCTR20000 29638100compared to IFN-αRuxolitinibNCT04338958200-RuxolitinibNCT0433166564-SarilumabNCT04327388300-SarilumabNCT04322773200compared to standard treatment and tacilizumabSarilumabNCT0434187060combined with azithromycin and hydroxychloroquine; compared with sarilumabSarilumabNCT04315298400-SarilumabNCT043219931000compared to baricitinib, hydroxychloroquine and lopinavir/ritonavirSildenafilNCT0430431310-SiltuximabNCT04329650100compared to methylprednisoloneSirolimusNCT0434167530-Sofosbuvir/DaclatasvirIRCT20200128 046294N270compared to standard treatmentTacrolimusNCT0434103884compared to standard treatment; combined with methylprednisoloneThymosinChiCTR20000 29541100combined with darunavir/cobicistat or lopinavir/ritonavirThymosinChiCTR20000 29806120compared to Camrelizumab and conventional treatmentTJ003234NCT04341116144-TocilizumabChiCTR20000 29765188compared to standard treatmentTocilizumabChiCTR20000 3019660-TocilizumabChiCTR20000 30442100-TocilizumabNCT04310228150compared to favipiravir; combined with favipiravirTocilizumabNCT0431548030-TocilizumabNCT04317092400-TocilizumabNCT0433971220compared to anakinraTocilizumabNCT04331808240-TocilizumabNCT04322773200compared to sarilumab and standard treatmentTocilizumabNCT0433530524compared to standard treatment; combined with pembrolizumabTocilizumabNCT04335071100-TocilizumabNCT0433291330-TocilizumabNCT04332094276compared with azithromycin + hydroxychloroquine; combined with azithromycin + hydroxychloroquineTocilizumabNCT0433179550-TocilizumabNCT04330638342compared with anakinra and siltuximab; combined with anakinra and siltuximabTocilizumabNCT04320615330-TofacitinibNCT0433204250-TradipitantNCT04326426300-Tranexamic acidNCT0433812660-Tranexamic acidNCT04338074100-TranilastChiCTR20000 3000260compared to standard treatmentTriazavirinChiCTR20000 30001240compared to standard treatmentUlinastatinChiCTR20000 30779100compared to standard treatmentUmifenovirChiCTR20000 29573480combined with IFN-α and lopinavir/ritonavirUmifenovirChiCTR20000 29621380compared to standard treatmentUmifenovirChiCTR20000 2999340-UmifenovirChiCTR20000 30254240compared to favipiravirUmifenovirNCT04252885125compared standard treatment and tolopinavir/ritonavirUmifenovirNCT04254874100combined with peginterferon α-2aUmifenovirNCT04255017400compared to lopinavir/ritonavir and oseltamivirUmifenovirNCT0427376360combined with bromohexine, favipiravir and IFN α-2bValsartanNCT04335786651-[^1][^2][^3][^4]Fig. 2Summary of clinical trials on COVID-19 treatment.The chart summarizes the clinical trials to date (16^th^ of April 2020), which verify the effectiveness of different potential anti−COVID therapeutic agents, with regard to the therapeutic agent and the number of participating patients.Fig. 2

Another study compiling the results of over 100 patients showed that the addition of CQ phosphate is superior to standard supportive care and hence contributing to prevention of the deterioration of pneumonia. Investigators observed improved lung imaging findings, improved negative conversion, and shortening of the disease course. No severe adverse events were noted in the study. CQ phosphate was recommended to be introduced into the next edition of National Health Commission of the People's Republic of China guidelines on prevention, diagnosis, and treatment of pneumonia caused by COVID-19 ([@bib0240]).

In February 2020, a randomized clinical trial on 62 patients was established in Renmin Hospital of Wuhan University to determine the efficacy of HCQ in patients with COVID-19. The trial involved 5-day HCQ treatment (400 mg/day), during which patients were examined 3 times a day, including temperature measurement and assessment of cough. CT was performed at baseline and once again after 5 days. In the HCQ arm, significantly shorter body temperature normalization and cough remission times were noted. In addition, radiological improvement in pneumonia was observed more frequently in patients from the HCQ group (80.6 % vs 54.8 %). Despite the rather limited sample size, the trial demonstrated that the use of HCQ can improve patient prognosis, accelerate remission, and improve clinical status ([@bib0125]).

Teng et al., showed that administration of HCQ in patients with persistent mild to moderate COVID-19 did not improve the probability of negative conversion, in comparison with standard of care alone. One hundred and fifty patients were included in this study, with 75 assigned to HCQ plus standard of care, whereas the remaining 75 patients were treated with standard of care only. Results of HCQ group did not differ significantly from the results of the standard of care group ([@bib0550]).

In a recent study, HCQ administration resulted in earlier recovery, without affecting overall mortality. The study was conducted on a group of 522 patients, 127 of which were symptomatic, while the remaining 395 patients had no clinical manifestations at baseline. Their COVID-19 status was confirmed by RT-PCR. Asymptomatic patients treated with HCQ recovered earlier (average recovery time = 5.4 days) compared to asymptomatic patients who did not receive any treatment (average recovery time = 7.6 days) ([@bib0065]).

In conclusion: CQ is a cheap and relatively safe drug that has been in clinical use for over 70 years ([@bib0155]; [@bib0145]), therefore can be a potential candidate for SARS-CoV-2 treatment ([@bib0175]). Despite promising results, it is essential to consider all safety measures and treat with this medication only as a supplementary form of treatment. Moreover, the initial enthusiasm surrounding HCQ and CQ was curbed after both were discontinued from SOLIDARITY trial due to the lack of benefit ([@bib0605]). This, along with other promising treatment schemes that have emerged in the recent months, are summarized in [Table 2](#tbl0010){ref-type="table"} .Table 210-day treatment algorithms of COVID-19, according to 6^th^ edition of Guidelines for the Prevention, Diagnosis, and Treatment of Novel Coronavirus-induced Pneumonia ([@bib0210]; [@bib0135]).Table 2DrugDoseChloroquine phosphate500 mg every 12 hours, orallyIFN-α5 million units every 12 hours, nebulized solutionRibavirin500 mg every 8 - 12 hours, iv - in combination with IFN-α (5 million units every 12 hours, nebulized solution) or lopinavir/ritonavir (200 mg/50 mg every 12 hours, orally)Umifenovir200 mg every 8 hours, orally[^5]

The antiparasitic agent ivermectin is another drug worth exploring further. In an *in vitro* study, it showed a 99.98 % reduction in viral load after 48 h of treatment ([@bib0095]). The drug is not toxic at a standard dose, and is safe for pregnant women, which makes it a strong candidate for evaluation in clinical trials ([@bib0095]). So far, one study has been established to verify its clinical efficacy, in combination with HCQ (NCT04343092) ([@bib0565]).

Corticosteroids {#sec0015}
===============

The WHO states in his recommendations that systemic steroids should not be routinely administered in treatment of viral pneumonia or acute respiratory distress syndrome (ARDS), unless recommended for other medical reasons, or as part of a clinical trial ([@bib0615]). In a systemic review of observational studies that focused on the effects of corticoid administration to patients with SARS, no clinical benefit was noted in terms of overall survival. In the case of influenza, steroid administration was associated with higher mortality rate and superimposed infections ([@bib0310]). General quality of evidence advocating for the use of steroids is considered weak. Another study, adjusted for confounding factors, did not present any association of steroid therapy with lower mortality rates. Finally, the latest study on steroids administration in patients with MERS, no effect on survival was disclosed, but steroids may have been responsible for halting the disease progression in severe forms of LRTI. The use of steroids was associated with delayed clearance of viral RNA from the respiratory tract ([@bib0040]) and blood ([@bib0380]). Given the evidence presently available, it is recommended to avoid the routine administration of steroids, unless recommended for the treatment of another comorbidity, e.g. shock or as continuation of treatment ([@bib0600]; [@bib0500]).

Antibiotics {#sec0020}
===========

There are several studies that present potential benefits of antibiotic therapy in coronavirus infection. It is challenging to elucidate the potential underlying mechanism of action that might be of benefit in monotherapy, therefore most researchers turn their attention to combination therapy. Azithromycin, a macrolide antibiotic, in combination with HCQ, might yield clinical benefit as an adjunctive. The insights from the French study (described in the section concerning CQ) presents the thesis that azithromycin potentiates the effects of therapy ([@bib0245]). Among patients treated with HCQ, 6 of them were given azithromycin (500 mg initially, then 250 mg per day for the next 4 days), in order to prevent superimposed bacterial infections. When comparing HCQ monotherapy to combination therapy with azithromycin, the percentage of patients who presented with negative PCR viral load was significantly different, at 3, 4, 5 and 6 days of follow-up, in the favor of dual therapy. On day 6, 100 % of patients were declared viral load-negative, in comparison with 57.1 % in HCQ monotherapy group and 12.5 % in control group (p \< 0.001). The effect of treatment was significantly more pronounced in patients with URTI and LRTI in comparison with asymptomatic patients (p \< 0.05) ([@bib0245]).

Teicoplanin is a glycopeptide antibiotic routinely used in the treatment of bacterial infections. In an *in vitro* setting it exerts anti-SARS-CoV activity. Therefore, it might be used as one of potential therapeutic agents against COVID-19. While it is most commonly used in Gram-positive bacterial infections, especially of Staphylococcal etiology, it did present some anti-viral properties in past studies. It is effective *in vitro* against Ebola virus, Influenza virus, Flavivirus, Hepacivirus C (HCV), human immunodeficiency virus (HIV), and coronaviruses -- MERS-CoV and SARS-CoV ([@bib0050]). In 2016, a patent application was submitted for the use of teicoplanin in MERS-CoV infection. According to Zhou et al., teicoplanin influences the early stages of viral replication cycle, inhibiting viral detachment, thereby preventing the release of viral RNA, halting further virus-cycle progression ([@bib0050]). Latest studies carried out by the same researchers, suggested that it is likewise effective against SARS-CoV-2 (as the target sequence, the molecular target for cathepsin L is identical to that of SARS-CoV). The teicoplanin concentration that is required to inhibit viral replication by 50 % (IC~50~; 50 % inhibitory concentration) *in vitro* was 1.66 μM, a value significantly lower than that reached in human blood (8.78 μM for a daily dose of 400 mg). These results require further confirmation in randomized clinical trials ([@bib0050]).

Viral entry inhibitors {#sec0025}
======================

Angiotensin converting enzyme 1 (ACE1) is a monocarboxypeptidase, which is responsible primarily for the conversion of angiotensin I (ATI) into angiotensin II (ATII), while angiotensin converting enzyme 2 (ACE2) is an enzyme that catalyzes the conversion of ATII into Angiotensin 1--7 that possesses vasodilatory properties. Type 2 pneumocytes present in the alveoli belong to the group of ACE2 expressing cells ([@bib0275]). Full-length ACE2 contains a structural transmembrane domain, which anchors its extracellular domain to the plasma membrane. The extracellular domain has been demonstrated as a receptor for the spike (S) protein of SARS-CoV-2 ([Fig. 3](#fig0015){ref-type="fig"} ) ([@bib0055]).Fig. 3Molecular targets of therapeutic agents disrupting viral invasion.ACE2 (angiotensin converting enzyme 2) - the virus fuses with host cells and multiplies by binding to the ACE2 membrane receptor, with the aid of the receptor binding domain encoded in the SARS-fusion protein S (Spike) 2-CoV ([@bib0470]); TMPRSS2 -- the protease activates the process of cell fusion when protein S binds to ACE2; it induces receptor-dependent syncytium formation \[143\]; CD147 -- potential alternative mediator of invasion of host cells (its role is not well established) ([@bib0585]).Fig. 3

ACE inhibitors (ACE-I) are the basis for the treatment of heart failure with impaired left ventricular systolic function (ejection fraction \<40 %) of classes II---IV according to the New York Heart Association ([@bib0490]). They owe their popularity in clinical practice to well-established effects on reducing all-cause mortality and heart failure hospitalization rate ([@bib0490]; [@bib0510]; [@bib0220]). An alternative to ACE-I, mainly used in the case of side effects associated with inhibition of bradykinin degradation - including persistent dry cough, are AT1 receptor antagonists (AT1-A). Both groups belong to the most basic drugs used in the treatment of hypertension, which makes them two of the most commonly used medications in the world, especially in the elderly population.

Recent analysis of SARS-CoV-2 infected populations presents a relationship between increased age of the population and more severe disease course ([@bib0270]). Some researchers associate this phenomenon with the universal use of drugs that affect the renin-angiotensin-aldosterone system (RAA). In the early stages of the pandemic, a hypothesis was proposed where chronic use of ACE-I and AT1-A could lead to an increase in ACE2 in the pulmonary circulation, which in turn increases the number of receptors available for the virus ([@bib0230]), thus the risk of severe COVID-19 increases ([@bib0205]; [@bib0635]). However, the results of the recent animal and human studies do not support this theory ([@bib0105]; [@bib0530]; [@bib0440]; [@bib0235]; [@bib0020]).

On the other hand, a hypothesis has been proposed that the attachment of the virus to ACE2 during the development of pneumonia disrupts the homeostasis by violating the RAA system, which further aggravates the patient\'s condition. Thus, when used in patients developing fully-blown COVID-19, ACE-I and AT1-A can reduce symptoms and even reduce mortality ([@bib0200]; [@bib0535]). A trial on 651 patients (NCT04335786) aiming to verify whether the antihypertensive agent valsartan influences COVID-19 treatment outcomes is currently in progress ([@bib0255]). The knowledge gained thus far does not allow stating that long-term therapy with drugs inhibiting the cascade of reactions in the renin-angiotensin-aldosterone (RAA) system is associated with worse patient prognosis, while their immediate supply can save the patient. There is no reason to discontinue therapy with these groups of drugs after the infection is diagnosed ([@bib0105]; [@bib0530]; [@bib0440]; [@bib0235]; [@bib0020]; [@bib0025]).

The information obtained from mechanistic studies concerning the entry of the virus into cells, as well as the presumed association between the use of ACE-I and AT1-A with the cases, leads to the hypothesis implying potential effectiveness of controlling the virus by supplying the soluble form of ACE2. Soluble ACE2 would competitively compete for SARS-CoV attachment with receptors present on cell surfaces, preventing virion invasion of pneumocytes. *In vitro* studies support the above assumptions - soluble ACE2 limited the proliferation of SARS-CoV on the Vero-E6 cell line ([@bib0390]; [@bib0355]). In *in vitro* tests, ACE2 combined with the Fc fragment of the antibody neutralized the virus ([@bib0385]). The method described is currently not feasible, with numerous obstacles that need to be removed before this therapy can enter human testing phase. The development of bioinformatics sparks hope that the analysis of protein data banks will allow for faster discovery of a receptor for which SARS-CoV-2 proteins will be a high-affinity ligand ([@bib0445]). Currently, studies on an animal model are not being carried out, however, transgenic mice expressing the human form of ACE2 are achievable and it is likely a matter of time before research in this model begins ([@bib0055]).

The inhibitor for transmembrane serine protease 2 (TMPRSS2) would act similarly to the described soluble ACE2. The enzyme, together with the virus receptor (ACE2) is responsible for the virion\'s entry into the cell ([Fig. 3](#fig0015){ref-type="fig"}) ([@bib0285]).

Another point of focus for COVID-19 treatment associated with the mechanism of SARS-CoV-2 entry into the cell may be HR1 - a fragment of the S protein that is important for the virus in order to attach to the cell. For now, the results of *in vitro* and animal model tests are encouraging. OC43-HR2P peptide successfully inhibits coronavirus invasion. Its modified form - EK1 possesses even more desirable properties. Intranasal peptide administration has been shown to be effective in a murine model, while not causing any organ dysfunction ([@bib0625]).

Nucleotide and nucleoside analogs {#sec0030}
=================================

This group of drugs has been routinely used in the treatment of viral infections for many years ([@bib0420]; [@bib0330]; [@bib0495]; [@bib0325]; [@bib0150]; [@bib0460]). It is characterized by high affinity to viral enzymes and low affinity to human enzymes. Because of that feature, nucleotide and nucleoside analogs are capable of inhibiting viral DNA replication, reverse transcription, and virion protein biosynthesis. This effect is possible due to many mechanisms, of which premature termination and inhibition of nitrogenous bases synthesis are most notable ([@bib0415]; [@bib0045]).

SARS-CoV and SARS-CoV-2 RNA-dependent RNA polymerases are structurally similar -- they share 95 % identity in amino acid sequence ([@bib0445]). This fact accelerates research, as some substances previously tested during SARS epidemic might be found equally effective against COVID ([@bib0445]).

Remdesivir (GS-5734) is widely known from trials on patients infected with Ebola virus ([@bib0595]; [@bib0515]; [@bib0085]). This adenosine analog binds to viral RNA, leading to premature termination ([@bib0590]; [@bib0340]). Its effectiveness has already been proven *in vitro* ([@bib0575]). Remdesivir was used in the rhesus macaque model of MERS infection. It was effective if administered either before or after MERS-CoV infection. Remdesivir restricted lung injury, inhibited viral replication and improved medical condition ([@bib0670]; [@bib0190]). It was more effective than combined therapy lopinavir/ritonavir and interferon-1β in the animal model ([@bib0515]). Remdesivir was further introduced into clinical trials. Preliminary results suggest that it is safe for humans ([@bib0415]; [@bib0010]). The first COVID-19 patient in the USA presented clinical improvement following remdesivir administration ([@bib0295]).

Grein et al., reported on the results of a clinical trial with remdesivir, which began on January 25th, and ended on March 7th 2020. Remdesivir was given to patients with confirmed SARS-CoV-2 infection and oxygen saturation ≤94 % (either breathing atmospheric air or receiving oxygen support). Patients were treated with remdesivir intravenously for 10 days - 200 mg on the first day, and 100 mg daily over the next 9 days. Sixty-one patients from the USA, Canada, Japan, and Europe were initially included in the treatment group, 8 of which were subsequently excluded. During the median follow-up of 18 days, 36 patients (68 %) displayed an improved oxygen maintenance class. Moreover, 17 of 30 patients (57 %) assisted by mechanical ventilation were extubated. A total of 25 patients (47 %) were discharged and 7 patients (13 %) died. The mortality rate was 18 % (6 out of 34) among patients receiving invasive ventilation and 5 % (1 out of 19) among patients not receiving invasive ventilation. The risk of death was greater in patients aged 70 years or older (risk ratio compared to patients under 70 years old, 11.34; 95 % confidence interval (CI): 1.36--94.17) and among patients with higher serum creatinine at baseline (risk ratio per milligram per deciliter, 1.91; 95 % CI: 1.22--2.99). The risk ratio for patients receiving invasive ventilation compared to patients receiving non-invasive oxygen support was 2.78 (95 % CI: 0.33--23.19). Clinical improvement was seen in 36 of 53 patients (68 %) ([@bib0265]). However, other researchers have raised concerns regarding the methodology of this study and question its results ([@bib0170]).

Beigel et al., verified the effectiveness of remdesivir in a randomized trial involving a group of 1063 patients (NCT04280705). Their preliminary results are promising, as patients receiving this agent recovered significantly sooner than those who received placebo ([@bib0060]). Moreover, remdesivir has a positive recommendation of The European Medicines Agency in the treatment of COVID-19 ([@bib0610]). However, not all trials (NCT04257656) reported such favorable results -- in 237 patients, remdesivir was not associated with any clinical benefits ([@bib0580]).

Another drug - favipiravir (T-705, Avigan, Favipira) has been under investigation since mid-February 2020. Clinical Medical Research Center of the National Infectious Diseases, together with the Third People\'s Hospital of Shenzhen reported the first promising results. The trial conducted on 80 patients with COVID-19 indicated better results in patients treated with favipiravir than the group treated with lopinavir/ritonavir ([@bib0090]). Additionally, less side effects were noted in the treatment group ([@bib0090]; [@bib0210]). Pharmacokinetics of favipiravir are a cause of concern. This agent reaches significantly lower serum concentrations in critically ill patients than in healthy individuals ([@bib0320]). Nevertheless, favipiravir seems to be a safe therapeutic option ([@bib0485]). Other nucleotide analogs, which are under investigation for their potential effectiveness against SARS-CoV-19 include triazavirin, emtricitabine, and tenofovir ([Table 1](#tbl0005){ref-type="table"}) ([@bib0425]).

Lopinavir/ritonavir {#sec0035}
===================

The protease inhibitor lopinavir and its booster ritonavir were verified in trial ChiCTR2000029308 on 199 patients with laboratory-confirmed COVID-19 infection. Cao et al., did not observe any benefit of lopinavir/ritonavir treatment in comparison with standard care ([@bib0100]). Adverse effects, such as nausea, vomiting, and hypokalemia might lead to deterioration of the clinical condition, consequently causing discontinuation of treatment ([@bib0100]; [@bib0405]; [@bib0215]). Nevertheless, it is too soon to reject lopinavir/ritonavir altogether ([@bib0560]; [@bib0465]).

This drug might be by far more effective if combined with ribavirin or interferon-1β to reduce side effects and increase therapeutic potential ([@bib0630]). The first of aforementioned combinations has proven its effectiveness against SARS ([@bib0140]). The second led to better results than no antiviral treatment in an animal model ([@bib0110]). It is also under scrutiny in the MIRACLE trial, which seeks for an effective medication against highly fatal MERS ([@bib0200]; [@bib0045]). A phase 2 trial (NCT04276688) including 127 COVID-19 patients showed superiority of triple therapy (lopinavir/ritonavir, ribavirin and interferon-β1b) over lopinavir/ritonavir. The combined therapy alleviated symptoms sooner and accelerated viral clearance ([@bib0315]). Most recently, the WHO has announced that it will be discontinuing its lopinavir/ritonavir arm of SOLIDARITY trial, due to no clinical benefit in terms of mortality reduction ([@bib0605]).

Since the beginning of 2020 another HIV protease inhibitor - darunavir has been in the process of verification, with early results being promising ([@bib0210]).

Umifenovir {#sec0040}
==========

Umifenovir (arbidol) has been investigated in the past as a potential drug for SARS and MERS ([@bib0415]). Its mechanism of action is similar to Imatinib, an Abelson kinase inhibitor (Abl), the anchor drug in the treatment of Chronic Myeloid Leukemia. Both of these molecules prevent virus binding to the cell membrane ([@bib0210]; [@bib0165]).

A trial on 33 adults with laboratory proven COVID-19, who had not been invasively ventilated has reached encouraging favorable results -- joint therapy of umifenovir and lopinavir/ritonavir was more efficacious than lopinavir/ritonavir only ([@bib0195]). Patients treated not only with protease inhibitor, but also with umifenovir became sooner SARS-CoV-19-negative (nasopharyngeal specimens) and more of them were found to improve radiologically, according to CT scans ([@bib0195]). As reported by Deng et al., umifenovir might decrease both the risk of SARS-CoV-19 transmission and the risk of acute respiratory distress syndrome (**ARDS)** ([@bib0195]). Other studies on the effectiveness of umifenovir showed its superiority in comparison with lopinavir/ritonavir ([@bib0705]), potency to reduce COVID-19 symptoms and accelerate the recovery time ([@bib0130]), but also underlined the lack of significant differences between umifenovir combined with IFN-α2b and IFN-α2b alone ([@bib0640]) or lack of SARS-CoV-2 clearance acceleration ([@bib0400]). However, meta-analysis of 12 studies with 1052 patients reached statistical significance only in higher negative rate of PCR after 14 days of treatment (RR = 1.27, 95 % CI = 1.04--1.55). Huang et al., concluded that there is no evidence that umifenovir improves COVID-19 outcomes ([@bib0305]).

TMPRSS2 inhibitor (Camostat mesylate) {#sec0045}
=====================================

SARS-CoV-2 infection depends on ACE2 and TMPRSS2 host cell factors ([Fig. 3](#fig0015){ref-type="fig"}) ([@bib0675]). TMPRSS2 is believed to be involved in the process of S protein priming, a vital step in SARS-CoV-2 viral entry ([@bib0285], [@bib0290]). This cellular protease can be blocked by the clinically proven protease inhibitor camostat mesylate. This drug is theoretically capable of preventing viral infection of the host cell. Thus, it should be considered as a potential therapeutic agent for COVID-19 infection ([@bib0385]). Camostat mesylate is approved in Japan for the treatment of pancreatitis. During a study on SARS-CoV-2 isolated from a patient, camostat mesylate managed to prevent the virus from entering lung cells ([@bib0290]). Currently, seven clinical trials (NCT4353284, NCT04455815, NCT04435015, NCT04321096, NCT04338906, NCT04374019, NCT04355052; earliest estimated completion date: December 2020) are ongoing that evaluate its clinical efficacy.

Tocilizumab {#sec0050}
===========

Roche Pharmaceuticals reported on a collaboration with FDA to launch a randomized, double-blind, placebo-controlled phase III clinical trial to assess the safety and efficacy of tocilizumab with standard care in hospitalized adult COVID-19 patients with severe pneumonia, compared to placebo in combination with standard care. Tocilizumab, a humanized monoclonal antibody against interleukin-6, is an immunosuppressive drug intended primarily for the treatment of rheumatoid arthritis ([@bib0160]). In China, it is expected to have a beneficial effect on coronavirus patients with severe lung damage and elevated interleukin 6 levels ([@bib0160]; [@bib0280]).

A non-randomized, open-label clinical study involved 21 patients with severe or critical COVID-19 infection treated intravenously with tocilizumab. The clinical stage of four patients was classified as critical (19 %). All patients received standard of care, including lopinavir and methylprednisolone, as well as tocilizumab at a dose of 400 mg intravenously either in one or two doses. Eighteen patients (85.7 %) received tocilizumab once, and three patients (14.3 %) received tocilizumab twice, with the second dose being administered due to recurrent fever within 12 h of first administration. After receiving tocilizumab, all patients experienced fever resolution within 24 h, with reported improvement of clinical symptoms. In 15 out of 20 patients (75 %), there was a statistically significant decrease in oxygen demand from the fifth day after receiving tocilizumab. Additionally, in 19 patients (90.5 %), CT scan showed resolution of radiological abnormalities and mean CRP levels markedly decreased on day 5. None of the patients died during the course of the study. Nineteen patients (90.5 %) survived until discharge, and 2 remained in the hospital until the end of the follow-up period. During the clinical trial period, no significant adverse reactions related to tocilizumab treated were reported ([@bib0645]).

In a retrospective cohort study on 51 COVID--19 patients, individuals with lung infiltrates and elevated inflammatory markers received a single dose of tocilizumab, if no contraindications were present. Additionally, systemic steroid, HCQ, and azithromycin were concomitantly used for the majority of patients. During the course of the study, 28 patients (55 %) received tocilizumab and 23 (45 %) did not receive. Tocilizumab cohort required more invasive ventilation (68 % vs 22 %) at baseline, as well as during the entire time of hospitalization (75 % vs 48 %). The median duration of vasopressor support and invasive mechanical ventilation in tocilizumab vs no tocilizumab cohorts was 2 days (IQR: 1.75--4.25 days) vs 5 days (IQR: 4--8 days), p = 0.039. Similar rates of hospital--acquired infections occurred in both cohorts. The authors concluded that tocilizumab administration was followed by rapid clinical improvement of COVID-19 pneumonia with ARDS ([@bib0555]).

Meplazumab {#sec0055}
==========

H. Bian et al., have recently published the results of a clinical trial investigating the new humanized anti-CD147 monoclonal antibody - meplazumab. CD147 (extracellular matrix metalloproteinase inducer -- EMMPRIN; basigin), a protein crucial for *Plasmodium falciparum* invasion ([@bib0185]), possibly plays a role in the interaction between spike protein of SARS-CoV-2 and lung epithelial cells ([Fig. 3](#fig0015){ref-type="fig"}) ([@bib0585]). In the study, 17 patients were given 10 mg meplazumab intravenously on day 1, 2 and 5, while 11 patients served as the control group. Patients treated with meplazumab, were discharged significantly faster and the severity of the disease was decreased. The time to negative viral load was also reduced. No side effects were noted during the study. Due to the small group, this drug requires further research, but the initial results are promising ([@bib0070]).

Other therapeutic options {#sec0060}
=========================

The use of interferon α and β is heavily disputed ([@bib0505]). Both substances are associated with serious side effects. While their administration in the early stages of the disease is associated with the expected positive effect, a delayed administration may intensify the cytokine storm, causing inflammation and consequentially worsening the patient\'s condition ([@bib0670]).

Coronaviruses require two proteases for successful protein biosynthesis: 3CLpro and PLpro ([@bib0450]). Without them, replication and generation of virions is impossible. These proteins, like RNA polymerases, are characterized by great sequence similarity between the forms found in SARS-CoV and SARS-CoV-2 ([@bib0445]). The use of inhibitors to these proteases, previously tested in the context of SARS, is currently under consideration ([@bib0360]; [@bib0695]). Summary of research into the most important drugs is presented in [Table 3](#tbl0015){ref-type="table"} .Table 3Summary of the progress in research on COVID-19 drugs. Source: drugvirus.info ([@bib0225]).Table 3DrugStage of researchSourceumifenovirIV phase([@bib0195])lopinavir/ritonavirIII/IV phase([@bib0100])hydroxychloroquineIII phase([@bib0245])remdesivirIII phase([@bib0340])favipiravirII phase([@bib0210])chloroquineresearch on cell lines([@bib0030]; [@bib0035])ribavirinresearch on cell lines([@bib0200])cepharanthineresearch on cell lines([@bib0180])mefloquineresearch on cell lines([@bib0180])

Statins are some of the most commonly prescribed drugs, especially in elderly patients. They induce ACE2 expression, which raises concerns about potentially increased risk of SARS-CoV-2 infection. Zhang et al., conducted a retrospective study in which they showed that the risk for 28-day all-cause mortality was 5.2 % and 9.4 % in the matched statin and non-statin groups of COVID-19 patients, respectively, with an adjusted hazard ratio of 0.58 ([@bib0680]).

In March 2020, the pharmaceutical company PharmaMar announced that Aplidine (Plitidepsin), a medicine commonly used to treat multiple myeloma, has antiviral activity ([@bib0475]). *In vitro* studies showed that Plitidepsin affects EF1A (eukaryotic translation elongation factor 1 alpha 1), which is key to multiplication and spread of the virus ([@bib0475]). The antiviral activity of plitidepsin was initially analyzed in a human hepatoma cell line infected with the HCoV-229E-GFP virus, which is similar to SARS-CoV-2. The preliminary results are promising, but a multicenter, randomized proof of concept (Phase 1) clinical trial is ongoing and patients are currently being recruited (NCT04382066) ([@bib0480]).

Scientists are beginning to consider utilizing immunomodulatory therapies to treat COVID-19 infection ([@bib0425]). The use of drugs that increase the inflammatory response and reactivity of leukocytes can, on one hand, aid in combating the infection, but, on the other hand, could expose the body to the negative effects due to exacerbation of the inflammatory response. There are numerous clinical trials investigating drugs such as anti-PD1 antibodies, recombinant IL-2, recombinant human granulocyte colony-stimulating factor (rhG-CSF), all of which are summarized in [Table 1](#tbl0005){ref-type="table"}. Previously used in cancer therapy, they can alter the inflammatory response, thereby reducing the negative effects of infection such as pulmonary fibrosis or sepsis.

Concluding remarks and future perspectives {#sec0065}
==========================================

In addition to the drugs discussed in the current review, many antiviral drugs have been explored for COVID-19 treatment for several months, without any positive effect. Neuraminidase inhibitors, known from influenza therapy: baloxavir marboxil, oseltamivir, paramivir, and zanamivir were used, especially in the first weeks of the epidemic ([@bib0425]; [@bib0395]). Other drugs tested to date include thymidine kinase inhibitors (acyclovir and ganciclovir), translation-inhibiting mRNA encapsulation inhibitor - ribavirin, nafamostat - successful in the treatment of MERS, nitazoxanide - used to control helminthiasis and currently tested for viability in viral infections, another nucleotide analog -- penciclovir, as well as drugs known from HCV therapy (azvudine, danoprevir/ritonavir, sofosbuvir/daclatasvir, and sofosbuvir/ledipasvir) ([@bib0575]; [@bib0200]; [@bib0425]). None of the above drugs is currently recommended for the treatment and support of treatment in SARS-CoV-2 infection ([@bib0395]). Due to the lack of an effective COVID-19 therapeutic protocol, prevention of infection is pivotal.

In addition to isolating the sources of infection and following thorough hygienic measures, it seems essential to focus on the development of a vaccine. Effective inactivated or recombinant vaccines, possibly developed in one of currently conducted trials (NCT04283461, NCT04299724 or NCT04313127), that could also be used in immunocompromised individuals, thanks to the advancement of biotechnology, are likely to be achieved much sooner than the registration of the first SARS-CoV-2 drugs. The insights gained by researchers during the development of vaccines against MERS and SARS might prove invaluable. All of these ideas are very compelling, but more research is needed, especially on large, randomized and controlled trials to confirm the efficacy of agents in the combat against the new coronavirus.

The COVID-19 pandemic is an unprecedented health, economic and humanitarian crisis that has major and ongoing impact on people in every country around the world. It is also an example of unprecedented cooperation of scientists from every country united to find a cure and vaccine against one single pathogen, but also searching for future solutions. Apart from finding efficacious treatments against COVID-19, it is necessary to accommodate the needs of patients suffering from the complications of COVID-19, including pulmonary fibrosis ([@bib0375]), central and peripheral neuropathies, delirium ([@bib0345], [@bib0350]), depression and many other complications. Further research towards in-depth understanding of the pathological mechanisms of SARS-CoV-2 in humans is necessary to develop novel therapeutic drugs for COVID-19.

The complex aspects of SARS-CoV-2 infection mandates collaboration of scientists from different disciplines including basic, clinical and engineering fields to enhance the probability of success against this life-threatening pandemic ([@bib0435]). As viral infection hijacks fundamental mechanisms of mammalian cell physiology ([@bib0015]; [@bib0660]), besides potential vaccine development strategy, combination of antiviral treatment in the presence of targeting these pathways could have the highest rate of success on overcoming this COVID-19 pandemic. Among these mechanisms, autophagy and unfolded protein response (UPR) received the attention of many research groups and important commentary papers and suggestions have been recently published ([@bib0520]; [@bib0080]; [@bib0570]; [@bib0545]). SARS-CoV-2 infection probably involves autophagy pathway like many other respiratory viral infections ([@bib0665], [@bib0655]). Some useful adjuvant therapy strategies like chloroquine or statins has common effects including regulation of cytokine storm and inflammation and inhibition of autophagy flux ([@bib0520]; [@bib0080]; [@bib0525]). On the other hand, SARS-CoV-12 infection probably induces UPR in the infected cells as it significantly increases protein biosynthesis in the infected cells like other coronaviruses ([@bib0545]). UPR is involved in regulation of autophagy and in the cellular secretome ([@bib0250]; [@bib0410]). Therefore, simultaneous targeting of autophagy/UPR pathway using FDA-approved compounds including chloroquine, statins, or drugs that are on their Phase-I or Phase-II clinical trials (MKC8866 to target IRE1 RNase activity) and antiviral therapy regimens could be an ideal strategy to control COVID-19 pandemic and help high risk patients to increase survival. This strategy will also potentially decrease significant amount of cost for taking care of COVID-19 patients in ICU units and decrease the demand for ventilators. The COVID-19 pandemic is likely to be controlled in the future with close collaboration of different science disciplines.

The WHO SOLIDARITY trial is ongoing and the results of this trial are anxiously expected by both researchers and clinicians. This large international multicenter study with thousands of COVID-19 patients will have the statistic power to finally prove or reject many hypotheses about COVID-19 therapy ([@bib0365]). This SOLIDARITY trial will test remdesivir, lopinavir/ritonavir, lopinavir/ritonavir combined with interferon-β, HCQ/CQ. As of 5^th^ of July 2020, two of those arms have been discontinued -- lopinavir/ritonavir and HCQ/CQ, due to the lack of benefit ([@bib0605]).

[^1]: IFN - interferon

[^2]: rSIFN-co - Recombinant Super-Compound IFN

[^3]: RhACE2 - Recombinant Human Angiotensin-converting Enzyme 2

[^4]: rhG-CSF - Recombinant human granulocyte colony-stimulating factor

[^5]: IFN-α - interferon-α.
